secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001493152-24-030495
Event type: leadership
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Hepion Pharma's interim CEO/CFO resigns; executive chairman takes over
----------------------------------------------------------------------

- John Cavan departed as interim CEO and CFO on August 5, 2024 for personal reasons.
- John Brancaccio, executive chairman, appointed interim CEO and CFO effective August 6.
- Company is a clinical-stage biotech (HEPA) with no named permanent successor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000149315224030495/0001493152-24-030495-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000149315224030495/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-030495

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer